BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dacomitinib PF-00299804 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dacomitinib PF-00299804\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04946968-1969@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dacomitinib PF-00299804: Phase 2 readout est. (NCT04946968)
DESCRIPTION:Dacomitinib PF-00299804\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced S
 olid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomark
 ers\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04946968
URL:https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1969@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dacomitinib PF-00299804: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Dacomitinib PF-00299804\, phase 2.\nStudy: The Drug Rediscovery
  Protocol (DRUP Trial)\nEstimated primary completion: September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dacomitinib-pf-00299804#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02925
 234
URL:https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1969@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Dacomitinib PF-00299804: Phase 3 readout est. (NCT06486142)
DESCRIPTION:Dacomitinib PF-00299804\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Stu
 dy\nEstimated primary completion: September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
